INTRODUCTION {#S1}
============

Although obesity is linked to metabolic dysregulation, the distribution of body fat strongly influences its risk to health ([@R33]; [@R46]; [@R60]). Visceral adiposity in humans is associated with insulin resistance, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis, while subcutaneous fat distributions may be benign or even protective ([@R36]; [@R42]; [@R48]). Up to 50% of obese adults are considered ''metabolically healthy'' based on varying criteria, and these individuals are typified by expanded subcutaneous, but reduced visceral and intrahepatic, fat distributions ([@R14]). Although women generally have higher percentages of total body fat than men, pre-menopausal women exhibit predominantly peripheral fat distributions, improved insulin sensitivity, and reduced susceptibility to type 2 diabetes mellitus (T2DM) ([@R43]). Overall, these observations suggest a healthful, sexually dimorphic role for subcutaneous adiposity to buffer overnutrition, which can be associated with reduced visceral or ectopic lipid accumulation and metabolic disease ([@R14]; [@R62]).

Adipose tissue expands through adipocyte hypertrophy and hyperplasia in a depot-specific manner to preserve whole-body metabolic homeostasis in the setting of nutrient excess ([@R49]). In mice, recent cell tracking studies have revealed that high-fat feeding in males expands the subcutaneous adipose tissue (ScAT) exclusively via adipocyte hypertrophy, whereas perigonadal fat may also expand via adipogenesis but only after several weeks of dietary challenge ([@R26]; [@R66]). By contrast, female mice exhibit both adipocyte hypertrophy and adipogenesis in subcutaneous and perigonadal fat pads in response to high-fat feeding ([@R27]). The extent to which these different modes of expansion contribute to metabolically ''healthy'' or ''unhealthy'' obesity is incompletely defined.

Major advances in our understanding of adiposity and insulin sensitivity have emerged from studies of transcription factors ([@R47]; [@R52]). PPARg and C/EBPs function as the central, pioneering factors to establish the early chromatin state necessary for white adipocyte differentiation, and many others play important collaborative roles, including SREBPs, STAT5, GR, and EBF1, by modulating their activity. Beyond adipogenesis, dynamic transcriptional programming in differentiated adipocytes by PPARg, SREBP, ChREBP, IRFs, LXRs, and other transcriptional activators impacts lipid storage and response to insulin as well as whole-body physiology. Thus, further work to decipher transcriptional regulators of the adipocyte may provide new insights into obesity and targets for metabolic therapy.

Although much is known about transcriptional activators, the role for repressors in metabolic tissue programming is less understood. Among these, our attention turned to the transcriptional repressor B cell lymphoma 6 (BCL6) as a potential regulator of adiposity. BCL6 is a member of the ZBTB family of C2H2-type zinc-finger transcription factors. Although first discovered for its roles in B and T cell development, immunity, and cancer ([@R4]), BCL6 is broadly expressed in metabolic organs. In liver and adipocytes, BCL6 is not only a gene target of growth hormone signaling, but BCL6 protein can physically compete with the nuclear effector of growth hormone, STAT5, at a subset of genomic binding sites ([@R10]; [@R34]; [@R37]; [@R74]). Although cell-type-specific functions for BCL6 outside of the immune system remain undefined, analysis of whole-body knockout mice indicated a potential role for BCL6 in lipid regulation but was confounded by co-occurring defects in immunity and severe inflammatory pathology ([@R32]). Finally, a recent report using short hairpin RNA (shRNA) knockdown in C3H10T1/2 cells indicated a possible role for BCL6 in promoting adipogenesis ([@R24]). These observations together raised the question of the *in vivo* role for BCL6 in adipose tissue.

Here, we use adipocyte-specific *Bcl6* knockout (Bcl6^AKO^) mice to discover a role for *Bcl6* ablation to increase ScAT mass during development and to enhance whole-body insulin sensitivity. Using a combination of transcriptomics, chromatin immunoprecipitation sequencing (ChIP-seq) in primary adipocytes, stable isotopic labeling *in vivo*, and lipidomics, we reveal that loss of BCL6 directly upregulates genes controlling growth pathways as well as fatty acid saturation, elongation, and thioesterase enzymes to enhance the production of fatty acids, phospholipids, glycerolipids, sphingolipids, and fatty acid esters of hydroxy fatty acids (FAHFAs) in ScAT. Despite their enhanced adiposity, Bcl6^AKO^ animals exhibit reduced ectopic fat deposition and enhanced hepatic insulin signaling. These results identify BCL6 as a developmental determinant between subcutaneous and visceral adipose tissue expansion and regulator of metabolic health.

RESULTS {#S2}
=======

BCL6 Is Highly Induced, but Not Required, during Preadipocyte Differentiation {#S3}
-----------------------------------------------------------------------------

To begin to understand the role for BCL6 in adipocytes, we interrogated BCL6 expression over the course of preadipocyte differentiation. *Bcl6* RNA was upregulated more than 15-fold during a 1 week *in vitro* transition of 3T3L1 preadipocytes to mature adipocytes, with peak *Bcl6* RNA levels corresponding to 7-fold increased BCL6 protein levels and the expression of mature adipocyte markers, including *Pparg*, *Cebpa*, *Lpl*, *Fabp4*, and *Adipoq* ([Figures1A--1C](#F1){ref-type="fig"}). We observed similar profiles in stromal vascular fraction (SVF)-derived primary preadipocytes from subcutaneous and perigonadal fat pads, as *Bcl6* expression was low in progenitors but increased by 10-fold in fully differentiated primary adipocytes ([Figure S1A](#SD1){ref-type="supplementary-material"}).

Next, to test the impact of BCL6 on adipogenesis, we isolated preadipocytes from SVFs of mice harboring floxed alleles of Bcl6 (Bcl6^fl/fl^) and a tamoxifen-inducible Cre recombinase (CAG-Cre-ER™) ([@R21]). We exposed Bcl6^fl/fl^ and Bcl6^fl/fl^;CAG-CreER™ SVF-derived preadipocytes to tamoxifen or ethanol control solvent prior to initiating differentiation, which resulted in over 80% deletion of *Bcl6* in drug-treated cells from Bcl6^fl/fl^;CAG-Cre mice ([Figure S1B](#SD1){ref-type="supplementary-material"}). Genetic knockout of *Bcl6* had a neutral or positive effect on the subsequent expression of mature adipocyte markers, including *Pparg*, *Cebpa*, *Lpl*, *Fabp4*, and *Adipoq* ([Figure S1B](#SD1){ref-type="supplementary-material"}), and no impact on *in vitro* lipid accrual ([Figure S1C](#SD1){ref-type="supplementary-material"}) compared to tamoxifen-exposed preadipocytes from Bcl6^fl/fl^ mice. Together, these findings led us to conclude that *Bcl6* deletion had no apparent functional impact on adipogenesis.

Ablation of Adipocyte *Bcl6* during Fetal Adipose Development in Mice Expands ScAT {#S4}
----------------------------------------------------------------------------------

To explore the impact of BCL6 in adipocytes, in which BCL6 levels are high, we next crossed *Bcl6* floxed mice (Bcl6^fl/fl^) to mice expressing Cre recombinase from the *Adipoq* promoter ([@R13]) and generated animals constitutively deleted of *Bcl6* in adipocytes (Bcl6^AKO^ mice) ([Figure S1D](#SD1){ref-type="supplementary-material"}). Remarkably, we found that regular chow-fed adult male and female Bcl6^AKO^ mice exhibited increased mass and percentage of fat despite having body weights comparable to Bcl6^fl/fl^ or Adipoq*-*Cre^+^ control animals ([Figures 1D](#F1){ref-type="fig"}, [S1E, and S1F](#SD1){ref-type="supplementary-material"}). Using necropsy analysis and computed tomography (CT) scanning, we found that this expanded fat mass in Bcl6^AKO^ mice was due to a 2-fold increase in subcutaneous, but not perigonadal or brown, adipose tissue ([Figures 1E--1G](#F1){ref-type="fig"} and [S1G](#SD1){ref-type="supplementary-material"}).

To determine whether the expansion was due to adipocyte hypertrophy, hyperplasia, or both, we quantified adipocyte sizes and numbers. Notably, subcutaneous adipocyte diameters in H&E stained tissue sections were dramatically larger in male Bcl6^AKO^ animals ([Figure 1H](#F1){ref-type="fig"}). Over 60% of subcutaneous adipocytes in Bcl6^AKO^ mice were 30 to 60 microns or larger in diameter, while more than 75% of adipocytes in control animals were under 30 microns in diameter ([Figure 1I](#F1){ref-type="fig"}). Similar results were observed in female Bcl6^AKO^ mice ([Figures S1H and S1I](#SD1){ref-type="supplementary-material"}). Additionally, this size difference was limited to ScAT and not seen in perigonadal adipose tissue (PgAT) ([Figures 1K](#F1){ref-type="fig"} and [S1J](#SD1){ref-type="supplementary-material"}). Consistent with our finding that BCL6-deficient preadipocytes undergo normal *in vitro* differentiation ([Figures S1B and S1C](#SD1){ref-type="supplementary-material"}), we found no evidence for hypercellularity in the adipose tissues of Bcl6^AKO^ mice ([Figure 1J](#F1){ref-type="fig"}).

High-Fat Diet Provokes Adipose Tissue Inflammation in Bcl6^AKO^ Mice {#S5}
--------------------------------------------------------------------

To assess the impact of BCL6 on fat accrual in response to overnutrition, we provided Bcl6^AKO^ mice with a high-fat diet (HFD) containing 45% of kcal from fat. Total fat mass more than quadrupled in all mice but remained significantly higher in Bcl6^AKO^ mice (average 17.6 g body fat) than Bcl6^fl/fl^ animals (average of 13.6 g body fat) after 12 weeks of diet ([Figure 1L](#F1){ref-type="fig"}). Upon necropsy, we found that progressive adiposity in Bcl6^AKO^ mice was predominantly due to increased ScAT, whereas PgAT was reduced by 30% compared to controls ([Figure S1K](#SD1){ref-type="supplementary-material"}). Although HFD caused adipocyte hypertrophy in all fat depots, subcutaneous adipocytes of Bcl6^AKO^ mice achieved significantly larger sizes, with nearly 50% of cells exhibiting cell diameters of over 60 microns in Bcl6^AKO^ mice compared to 25% of adipocytes in controls ([Figures S2A and S2B](#SD1){ref-type="supplementary-material"}). Interestingly, although the size distribution of perigonadal adipocytes was comparable between genotypes, the PgAT of Bcl6^AKO^ mice had increased interstitial cell infiltration and crown-like structures ([Figures S2C and S2D](#SD1){ref-type="supplementary-material"}). We examined inflammatory gene expression in high-fat-fed Bcl6^AKO^ and control mice, which demonstrated increased levels of the macrophage markers *F4/80* and *Cd11b*, elevated levels of M1 macrophage activation genes *Ccl2*, *IL-6*, and *Tnfa*, and reduced expression of the M2 markers *Retnla* and *Mgl2* in PgAT of Bcl6^AKO^ animals ([Figure S2E](#SD1){ref-type="supplementary-material"}). A similar but less robust expression pattern was observed in ScAT of Bcl6^AKO^ mice ([Figure S2F](#SD1){ref-type="supplementary-material"}). Additionally, we assessed vascularization markers since angiogenesis is critical for adipose tissue expansion and insufficiency leads to adipocyte hypoxia, death, and inflammation ([@R57]). Under chow-fed conditions, there was no qualitative difference in PECAM staining or quantitative difference in the expression of *Cd31*, *Cdh5*, *Tek*, and *Vegfa* ([Figures S2G and S2H](#SD1){ref-type="supplementary-material"}), but in HFD-fed Bcl6^AKO^ mice these transcripts were significantly reduced in both ScAT and PgAT compared to HFD-fed controls ([Figure S2I](#SD1){ref-type="supplementary-material"}). Thus, lack of BCL6 promoted the expansion of subcutaneous adipocytes and overall adiposity, while it simultaneously increased adipose tissue inflammation, attenuated angiogenic markers, and limited visceral fat expansion in the setting of overnutrition.

Loss of Adipocyte *Bcl6* Results in Whole-Body Insulin Sensitivity {#S6}
------------------------------------------------------------------

Subcutaneous body fat distribution is linked to improved glucose metabolism, yet hypertrophic adipocytes and adipose tissue inflammation have been correlated with insulin resistance ([@R16]). Given these opposing associations, we sought to determine whether *Bcl6* deletion in adipocytes would influence insulin sensitivity. In either regular chow-fed or HFD-fed male and female Bcl6^AKO^ mice, we observed significantly reduced fasting insulin and glucose levels compared to controls ([Figures 2A and 2B](#F2){ref-type="fig"}; data not shown). Moreover, calculated insulin resistance based on the Homeostasis Model Assessment was significantly reduced in Bcl6^AKO^ mice, suggesting improved glucose metabolism ([Figure 2C](#F2){ref-type="fig"}) ([@R7]). Next, we performed hyperinsulinemic-euglycemic clamps in HFD-fed Bcl6^AKO^ and Bcl6^fl/fl^ control mice. Remarkably, Bcl6^AKO^ mice required glucose infusion rates nearly double those of Bcl6^fl/fl^ controls to maintain steady-state glucose levels, indicating that *Bcl6* ablation in adipocytes dramatically enhanced overall insulin sensitivity ([Figure 2D](#F2){ref-type="fig"}). The rate of glucose disappearance (Rd) trended higher in Bcl6^AKO^ mice but did not reach statistical significance ([Figure 2E](#F2){ref-type="fig"}), while tissue-specific glucose uptake of ^14^C-deoxyglucose tracer revealed increased accumulation in gastrocnemius and vastus lateralis muscles as well as PgAT but decreased uptake into brown adipose tissue (BAT) ([Figure 2F](#F2){ref-type="fig"}). Although fasting free fatty acid levels were comparable between Bcl6^fl/fl^ and Bcl6^AKO^ mice, clamped levels were significantly lower in Bcl6^AKO^ animals ([Figure 2G](#F2){ref-type="fig"}), reflecting enhancement in their insulin-mediated suppression of lipolysis. More remarkably, however, the calculated rate of endogenous glucose production in Bcl6^AKO^ mice was reduced at all examined time points ([Figure 2H](#F2){ref-type="fig"}, left panel). When considered in the context of plasma insulin concentrations before and during the clamp ([Figures 2H](#F2){ref-type="fig"}, right panel), these results indicated that gluconeogenesis is markedly more sensitive to insulin-mediated suppression in Bcl6^AKO^ animals compared to controls. It is also notable that despite receiving equal rates of exogenous insulin infusion during the procedure, both pre-clamp and clamped plasma insulin levels were significantly lower in Bcl6^AKO^ mice ([Figure 2I](#F2){ref-type="fig"}). Since insulin signaling is coupled to hepatic insulin clearance ([@R12]), this result suggested dramatically enhanced insulin sensitivity in the livers of Bcl6^AKO^ mice. Thus, deletion of *Bcl6* in adipocytes, despite rendering mice more obese, improves insulin sensitivity predominantly through enhanced suppression of gluconeogenesis.

Expansion of Subcutaneous Fat Is Independent of Brown Fat Activity {#S7}
------------------------------------------------------------------

Bcl6^AKO^ animals exhibited decreased insulin-stimulated glucose uptake into BAT ([Figure 2F](#F2){ref-type="fig"}) and a slight tendency for increased body weight ([Figure 1D](#F1){ref-type="fig"}), raising the possibility of diminished brown fat activity and positive energy balance. To further examine this, we performed PET/CT scanning with \[^18^F\]fluoro-deoxyglucose (FDG) and identified a 25% reduction in basal BAT uptake in Bcl6^AKO^ mice ([Figure S3A](#SD1){ref-type="supplementary-material"}). Consistent with reduced BAT activity, RNA levels of some thermogenic markers, including *Ucp1*, *Prdm16*, and *Cidea*, were significantly reduced in Bcl6^AKO^ animals ([Figure S3B](#SD1){ref-type="supplementary-material"}). To determine changes in energy balance, we next compared Bcl6^AKO^ and Bcl6^fl/fl^ control mice using metabolic chambers to quantify VO~2~ and VCO~2~ by indirect calorimetry, calculate energy expenditure (EE) and respiratory exchange ratio (RER), and determine food intake and activity. Virtually no significant differences were revealed in any of these parameters ([Figures S3C--S3H](#SD1){ref-type="supplementary-material"}), although RER was lower in Bcl6^AKO^ animals at some time points ([Figure S3F](#SD1){ref-type="supplementary-material"}). Finally, to address whether decreased thermogenesis could influence the adiposity of Bcl6^AKO^ mice, we bred and continuously housed Bcl6^AKO^ and Bcl6^fl/fl^ control mice at 30^°^C. Even under thermo-neutral conditions, Bcl6^AKO^ mice exhibited increased total body fat as well as subcutaneous adipocyte cell size and tissue mass ([Figures S3I--S3L](#SD1){ref-type="supplementary-material"}). Overall, these findings indicated that *Bcl6* deletion in adipocytes may diminish BAT activity and energy expenditure, but short-term indirect calorimetry may lack the sensitivity to detect small differences at the whole-body level. However, reduced thermogenesis is unlikely to account for the white adipose tissue expansion of Bcl6^AKO^ mice, since thermoneutral conditions failed to minimize their increased body fat and its marked subcutaneous distribution compared to controls.

Constitutive *Bcl6* Ablation Increases ScAT *De Novo* Lipogenesis {#S8}
-----------------------------------------------------------------

We next investigated the functional impact of *Bcl6* ablation on adipocyte lipid metabolism to better understand why Bcl6^AKO^ mice develop subcutaneous adipocyte hypertrophy. To analyze the impact of BCL6 on lipogenesis, we followed the incorporation of ^2^H from a bolus of deuterated water into C-H bonds of newly formed palmitate and glycerol backbones of adipose tissue triglycerides in Bcl6^AKO^ and Bcl6^fl/fl^ mice. We identified 2-fold increased rates of *de novo* synthesis of triglyceride-bound palmitate ([Figure 3A](#F3){ref-type="fig"}) and triglyceride-bound glycerol ([Figure 3B](#F3){ref-type="fig"}) in the ScAT of Bcl6^AKO^ mice compared to Bcl6^fl/fl^ controls. Although trending higher, there was no significant difference in lipogenesis in the PgAT between genotypes ([Figures 3A and 3B](#F3){ref-type="fig"}).

To determine the impact of adipocyte BCL6 on lipolysis, we treated chow-fed Bcl6^AKO^ and Bcl6^fl/fl^ mice with the beta-3 adrenergic receptor agonist CL316,243 and sampled circulating free fatty acids (non-esterified fatty acids \[NEFAs\]) and glycerol over time ([Figure S4A](#SD1){ref-type="supplementary-material"}). We observed no difference in the concentrations of serum NEFAs or glycerol in Bcl6^AKO^ mice compared to controls. Additionally, we tested isoproterenol-stimulated glycerol and free fatty acid release from isolated ScAT depots *ex vivo*, which were also not significantly different between genotypes ([Figure S4B](#SD1){ref-type="supplementary-material"}). Finally, we exposed ScAT lysates to ^14^C-labeled palmitate and performed beta oxidation assays to determine changes in fatty acid oxidation. We detected comparable total rates of fatty acid oxidation in tissues from Bcl6^AKO^ and Bcl6^fl/fl^ mice based on combined quantities of completely oxidized ^14^C-labeled CO~2~ and incompletely oxidized acid soluble metabolites ([Figure S4C](#SD1){ref-type="supplementary-material"}). Thus, loss of BCL6 in adipocytes increased cell-intrinsic lipogenesis but did not functionally impact fatty acid oxidation or acute lipolytic responses to beta adrenergic agonists.

BCL6 Represses Growth and Lipid Biosynthetic Genes in Adipocytes {#S9}
----------------------------------------------------------------

To determine the transcriptional basis for subcutaneous adipocyte expansion following *Bcl6* ablation, we next determined the BCL6-regulated gene expression networks in inguinal ScAT and PgAT ([Figure 3C](#F3){ref-type="fig"}). Using mRNA sequencing to compare Bcl6^AKO^ and Bcl6^fl/fl^ mice, we identified 1,074 differentially regulated ScAT transcripts (adjusted p value \< 0.05) in males consisting of 570 upregulated and 504 downregulated genes. In PgAT, we identified 1,488 differentially regulated transcripts comprised of 759 upregulated and 729 downregulated genes. Although embryonic *Bcl6* ablation selectively expands subcutaneous adipocytes, we found that expression changes within the PgAT and ScAT of Bcl6^AKO^ mice were strongly correlated both in males (r = 0.78) and females (r = 0.72) ([Figures 3C](#F3){ref-type="fig"} and [S4D](#SD1){ref-type="supplementary-material"}). ScAT and PgAT expression changes due to *Bcl6* ablation were also highly correlated across sexes (ScAT, r = 0.80 and PgAT, r = 0.76) ([Figure S4E](#SD1){ref-type="supplementary-material"}; data not shown). Furthermore, integrative analysis of upregulated and downregulated transcripts in ScAT and PgAT revealed similar gene ontologies in both depots ([Figures 3D and 3E](#F3){ref-type="fig"}). We identified tyrosine kinase and developmental growth pathways among the top-scoring terms ([Figures 3D](#F3){ref-type="fig"}), which contained insulin or IGF signaling components implicated in growth, including *Igf2* and *Akt1*, and glycolytic regulators that drive glycerogenesis and NADPH production for lipid synthesis such as *Pdk3*. Carbohydrate metabolic process and biosynthesis of unsaturated fatty acids were other high-scoring ontologies for upregulated genes in the ScAT and PgAT of Bcl6^AKO^ mice, which consisted of *Fads1*, *Fads2*, *Elovl6*, *Hacd1*, *Asah1*, *Acot3*, *Acot4*, *Lpgat1*, *Cds2*, and other genes linked to lipid synthesis and adipose tissue expansion. Although ScAT and PgAT were categorically similar in many respects, ontologies related to immunity were selectively enriched among genes upregulated in PgAT ([Figure 3D](#F3){ref-type="fig"}), consistent with the proclivity for Bcl6^AKO^ mice to develop immune cell infiltration following a HFD ([Figures S2C and S2E](#SD1){ref-type="supplementary-material"}). Top-ranking ontologies for genes downregulated in ScAT and PgAT of Bcl6^AKO^ mice were related to fatty acid catabolism ([Figure 3E](#F3){ref-type="fig"}), which included genes involved in beta oxidation (*Acox1*, *Acsl5*, *Cpt2*, and *Ehhadh*) and lipolysis (*Adrb3*, *Lipe*, and *Pnpla2*). PTEN regulation was also significantly overrepresented as a term but limited to male ScAT, featuring *Pten* and genes encoding components of the proteasome.

Using qPCR, we confirmed enhanced transcription of unsaturated fatty acid biosynthesis and growth signaling genes, as well as reduced expression of lipolysis and fatty acid oxidation genes in ScAT, PgAT, and BAT of Bcl6^AKO^ mice ([Figures 3F](#F3){ref-type="fig"}, [S4H, and S4I](#SD1){ref-type="supplementary-material"}). We also interrogated established regulators of *de novo* saturated fatty acid synthesis (*Glut4*, *Scd1*, *Fasn*, and *Dgat*) and fatty acid uptake (*Cd36*, *Lpl*, and *Fatp1/4*), which were unchanged in both ScAT and PgAT ([Figures S4F--S4H](#SD1){ref-type="supplementary-material"}; data not shown) but significantly reduced in BAT of Bcl6^AKO^ animals ([Figure S4I](#SD1){ref-type="supplementary-material"}; data not shown). Thus, our data overall suggested that ablation of adipocyte *Bcl6* enhanced expression of anabolic mediators of growth and lipid synthesis while suppressing mRNAs for catabolic regulators of lipid oxidation and hydrolysis in ScAT, PgAT, and BAT.

Gene Signatures in BCL6-Deficient ScAT Overlap with Healthful Human Patterns {#S10}
----------------------------------------------------------------------------

Since Bcl6^AKO^ mice exhibit improved metabolism despite increased adiposity, we compared their gene networks to those in humans with metabolically healthy obesity ([@R14]). Using expression data from metabolically abnormal or metabolically normal obese (MNO) subjects who underwent subcutaneous fat biopsy before and after moderate weight gain, we found that gene pathways associated with metabolically healthy obese subjects clustered more closely with orthologous gene ontologies enriched in the subcutaneous fat of Bcl6^AKO^ mice, including categories of lipid and monocarboxylic acid metabolism, biosynthesis of unsaturated fatty acids, metabolism of carbohydrates, extracellular matrix organization, and vascular development ([Figure 3G](#F3){ref-type="fig"}). In particular, upregulation of genes involved in fatty acid biosynthesis, including *FADS1*, *FADS2*, *ELOV6*, and *HACD1*, was common to both MNO humans and Bcl6^AKO^ mice. Overall, these expression data linked *Bcl6* ablation in ScAT to lipid synthesis and tissue remodeling genes reminiscent of expression changes in humans with metabolically healthy obesity.

BCL6 Binds to DNA near Lipid Biosynthetic and Growth Regulatory Genes {#S11}
---------------------------------------------------------------------

BCL6 has been characterized as a transcriptional repressor in B cell and other immune lineages, but its direct regulatory impact on gene expression in metabolic tissues is unknown ([@R4]). We sought to examine the genomic context through which BCL6 governs adipocyte expansion by generating an adipocyte-specific form of the mammalian INTACT (isolation of nuclei tagged in specific cell types) system (Adipo-Sun1-sfGFP-myc mice) for *in vivo* ChIP-seq ([Figure 4A](#F4){ref-type="fig"}) ([@R38]). In primary inguinal subcutaneous adipocytes, we identified 1,784 BCL6 binding sites using a false discovery rate (FDR) cut-off of 0.1%. Ontology analysis for genes near BCL6 binding sites identified mouse phenotype terms that included decreased susceptibility to hepatic steatosis, increased insulin sensitivity, increased adiponectin level, decreased gonadal fat pad weight, abnormal white fat cell size, and others consistent with the ScAT phenotype of Bcl6^AKO^ animals ([Figure 4B](#F4){ref-type="fig"}).

In perigonadal adipocytes, we identified 3,956 BCL6 binding sites using the same FDR cut-off, with 510 binding sites in common with ScAT. Overall, BCL6 binding peaks were moderately correlated across depots (r~s~ = 0.23), and peaks common to both ScAT and PgAT exhibited the highest and most correlated signal strengths (r~s~ = 0.69) ([Figure S5A](#SD1){ref-type="supplementary-material"}). Ontologies and associated mouse phenotypes for genes in vicinity of these common binding sites included regulation of glucose and carbohydrate metabolism, generation of metabolites and energy, response to insulin stimulus, decreased susceptibility to hepatic steatosis, and decreased triglyceride level ([Figure S5B](#SD1){ref-type="supplementary-material"}). Both in ScAT and PgAT, BCL6 genome-wide DNA binding sites were strongly enriched for consensus BCL6 motifs and to a lesser extent recognition sequences for C/EBP, EBF, NF1, TEAD, STAT, and others ([Figure 4C](#F4){ref-type="fig"}).

Next, we integrated our RNA sequencing (RNA-seq) and ChIP-seq datasets using the Binding and Expression Target Analysis (BETA) pipeline to determine putative direct target genes for BCL6 and define its regulatory potential ([@R67]). We found that among genes that were transcriptionally altered by adipocyte BCL6 ablation and located within 100 kb of a BCL6 binding site, 134 genes (out of a total of 177) and 195 (out of 336) were upregulated by loss of BCL6 in ScAT and PgAT, respectively ([Figure 4D](#F4){ref-type="fig"}; [Table S1](#SD1){ref-type="supplementary-material"}), corresponding to a repressive regulatory potential (p value = 1.56e---7 \[ScAT\]; p value = 1.44e---6 \[PgAT\]) for BCL6 in adipocytes ([Figure S5C](#SD1){ref-type="supplementary-material"}). Gene ontologies for these directly bound, upregulated targets in Bcl6^AKO^ mice, including the *Fads1* and *Igf2* genes ([Figures 4E](#F4){ref-type="fig"} and [S5D](#SD1){ref-type="supplementary-material"}), were dominated by unsaturated fatty acid biosynthesis, kinase signaling, and cell growth pathways ([Figure 4F](#F4){ref-type="fig"}). In contrast, genes downregulated in Bcl6^AKO^ mice were not enriched in BCL6 binding sites compared to statically expressed genes (p value = 0.913 \[ScAT\], p value = 0.804 \[PgAT\]) ([Figure S5C](#SD1){ref-type="supplementary-material"}). Ontologies for directly bound downregulated genes included cholesterol metabolism, peroxisome organization, and water-soluble vitamins and cofactor metabolism that were common in both depots ([Figure 5G](#F5){ref-type="fig"}). Using ChIP-qPCR, we validated several binding peaks along directly regulated genes in ScAT and PgAT (*Igf2*, *Fads1*, *Acot1*, *Elovl5*, *Ccnd2/3*) and confirmed the absence of BCL6 at genomic regions lacking BCL6 ChIP-seq peaks (*Adipoq*, *Scd1*, *Fasn*) ([Figure S5D](#SD1){ref-type="supplementary-material"}). Over-all, our genomic studies indicated a direct role for BCL6 in the repression of anabolic signaling and lipid biosynthetic genes in ScAT and PgAT.

Ablation of Adipocyte BCL6 in Adult Mice Expands All White Adipose Tissue Depots {#S12}
--------------------------------------------------------------------------------

Transcriptomic and genome-wide binding analyses revealed similar BCL6-regulated networks in visceral and ScAT, yet increased fat mass and adipocyte size was only observed in the ScAT of Bcl6^AKO^ mice ([Figures 1E and 1I](#F1){ref-type="fig"}). To test whether developmental timing of *Bcl6* deletion influenced adipose tissue expansion, we developed a doxycycline (Dox)-inducible model to delete *Bcl6* in adiponectin-expressing adipocytes, herin denoted as i-Bcl6^AKO^ mice ([@R66]). At 8 weeks of age, i-Bcl6^AKO^ and control mice were treated with Dox for 7 days. Although baseline (pre-Dox) body compositions were comparable, fat mass became significantly higher in i-Bcl6^AKO^ mice within 4 weeks after treatment ([Figure S5E](#SD1){ref-type="supplementary-material"}). In contrast to Bcl6^AKO^ mice, Dox-treated i-Bcl6^AKO^ mice developed increased white adipose tissue in all depots, including the inguinal, inter-scapular, perigonadal, perinephric, and interscapular adipose tissues but not BAT ([Figure S5F](#SD1){ref-type="supplementary-material"}). Further, adipocyte size was increased in all white adipose tissue (WAT) depots, including ScAT and PgAT ([Figures S5G and S5H](#SD1){ref-type="supplementary-material"}). Together, these data indicated that de-repression of the BCL6 regulatory network has the potential to expand all white adipocytes but is compensated for during development within visceral depots.

Loss of Adipocyte BCL6 Increases Adipose Tissue and Circulating Lipokines and Adiponectin {#S13}
-----------------------------------------------------------------------------------------

To analyze the impact of BCL6 ablation in adipocytes on cellular and circulating lipid composition, we applied shotgun lipidomics to quantify \~ 250 individual species from the ScAT and serum of Bcl6^AKO^ and Bcl6^fl/fl^ animals. In ScAT of Bcl6^AKO^ mice, quantities of the reported insulin-sensitizing lipokines known as FAHFAs and C16:1n7-palmitoleate were more than twice as high compared to controls ([Figures 5A](#F5){ref-type="fig"}, [5B](#F5){ref-type="fig"}, and [S6A](#SD1){ref-type="supplementary-material"}) ([@R8]; [@R73]). Additionally, we observed increased levels of other triglyceride-associated fatty acyl chains and total triglycerides ([Figures S6A and S6B](#SD1){ref-type="supplementary-material"}), various membrane-associated and signaling glycerophospholipids, and sphingomyelin ([Figures S6C and S6D](#SD1){ref-type="supplementary-material"}). In contrast, we found no difference in the level of acylcarnitines in the adipose tissue of Bcl6^AKO^ mice ([Figure S6E](#SD1){ref-type="supplementary-material"}, left), in line with their unaltered fatty acid oxidation rate. In serum, we similarly detected 2.5-fold elevated levels of FAHFAs ([Figure 5A](#F5){ref-type="fig"}), including the 16:0H18:0 form (PAHSA), which has been directly correlated with human insulin sensitivity ([@R73]) ([Figure 5B](#F5){ref-type="fig"}, right). In contrast, circulating free palmitoleate levels were unchanged in Bcl6^AKO^ mice ([Figure S6A](#SD1){ref-type="supplementary-material"}, center), and levels of many other lipids were significantly reduced, including triglyceride-associated fatty acyl chains ([Figure S6A](#SD1){ref-type="supplementary-material"}, right), total triglycerides ([Figure S6B](#SD1){ref-type="supplementary-material"}, right), ceramides ([Figure 5C](#F5){ref-type="fig"}), and several glycerophospholipids ([Figure S6D](#SD1){ref-type="supplementary-material"}, right). As in adipose tissue, levels of acylcarnitines in the serum were unchanged in Bcl6^AKO^ animals ([Figure S6E](#SD1){ref-type="supplementary-material"}, right).

Additionally, we quantified circulating adipokines and inflammatory mediators. Consistent with the observed 50% reduction in ceramides, we detected ∼30% increased serum levels of adiponectin in regular chow-fed or HFD-fed Bcl6^AKO^ mice ([Figure 5D](#F5){ref-type="fig"}), which is known to induce ceramide degradation([@R22]). Levels of leptin were also significantly higher in chow-fed, but not HFD-fed, Bcl6^AKO^ animals ([Figure S6F](#SD1){ref-type="supplementary-material"}). Despite heightened inflammation in the adipose tissues of Bcl6^AKO^ mice ([Figures S2C, S2E, and S2F](#SD1){ref-type="supplementary-material"}), circulating adipo-kines associated with insulin resistance, including PAI-1, resistin, interleukin-6 (IL-6), TNFa, and CCL2, were unchanged in chow-fed or HFD-fed mice ([Figures S6G--S6K](#SD1){ref-type="supplementary-material"}). Thus, *Bcl6* ablation broadly altered adipocyte lipid content and conferred an insulin-sensitive pattern of circulating FAHFAs, ceramides, and adiponectin.

Adipocyte BCL6 Deficiency Potentiates Insulin Responses while Reducing Lipid Signaling, Steatosis, and Inflammation in the Liver {#S14}
--------------------------------------------------------------------------------------------------------------------------------

Based on our insulin clamp findings and the sensitizing profile of lipokines and adipokines in Bcl6^AKO^ mice, we next examined insulin signaling and gene regulation in liver to further define how loss of *Bcl6* conferred insulin sensitivity. Following insulin injection into chow-fed Bcl6^AKO^ and Bcl6^fl/fl^ animals, we observed enhanced liver phosphorylation of the insulin receptor (p-IR) and serine-473 of AKT (p-AKT), with 1.8-and 2.8-fold increased ratios of p-IR to total insulin receptor and p-AKT to total AKT, respectively, in Bcl6^AKO^ mice ([Figure 6A](#F6){ref-type="fig"}). Insulin-induced AKT signaling is known to direct *de novo* lipogenesis in the liver, which is exacerbated by insulin resistance ([@R61]). Thus, we used *in vivo* deuterium incorporation to measure *de novo* hepatic lipogenesis in chow-fed animals, finding rates reduced by 30% in Bcl6^AKO^ mice ([Figure 6B](#F6){ref-type="fig"}). We also revealed a signature of reduced lipid-directed transcription in their livers. RNA-seq of chow-fed mice identified 37 differentially regulated genes, of which 28 were downregulated in livers of Bcl6^AKO^ mice, including *Plin2* and *Pparg*, which have been previously implicated in steatosis ([Figure 6C](#F6){ref-type="fig"}) ([@R15]; [@R41]). These altered transcripts were predominantly related to PPAR signaling and associated lipid and carbohydrate metabolism ([Figure 6D](#F6){ref-type="fig"}), and their gene promoters were enriched in PPAR/RXR DNA binding motifs ([Figure 6E](#F6){ref-type="fig"}), consistent with a recent report that SREBP-directed hepatic *de novo* lipogenesis is a source for PPARa endogenous ligands ([@R17]). Thus, the liver transcriptional signatures of chow-fed Bcl6^AKO^ mice reflected a reduction in lipogenesis-driven, PPAR-activated gene expression.

At the level of tissue composition, we found that liver weights and triglyceride contents were significantly reduced by 13% and 48% in chow-fed or 20% and 44% in high-fat-fed Bcl6^AKO^ animals, respectively ([Figures 6F and 6G](#F6){ref-type="fig"}). Consistent with these quantitative assessments, histopathological examination of liver sections revealed that HFD-induced steatosis was strongly mitigated in Bcl6^AKO^ mice ([Figure 6H](#F6){ref-type="fig"}). These results indicate that loss of BCL6 in adipocytes exerts a protective effect on hepatic lipid accumulation.

Finally, since steatosis is often accompanied by hepatic inflammation, we used qPCR to interrogate the expression of macrophage markers and pro-inflammatory mediators in livers from high-fat-fed Bcl6^AKO^ and control mice. In contrast to the pro-inflammatory changes observed in adipose tissue ([Figures S2E and S2F](#SD1){ref-type="supplementary-material"}), hepatic expression of *F4/80*, *Ccl2*, and *Tnfa* were each significantly reduced and *Cd11b* and *Il1b* trended lower in Bcl6^AKO^ mice ([Figure 6I](#F6){ref-type="fig"}). In sum, these findings revealed that loss of BCL6 in adipocytes enhances liver insulin sensitivity, which is accompanied by diminished hepatic lipid accumulation and lipid-driven PPAR and pro-inflammatory transcription.

DISCUSSION {#S15}
==========

We have described a mouse model of healthful obesity in Bcl6^AKO^ mice characterized by expanded ScAT and marked insulin sensitivity. Adipocyte *Bcl6* deletion both enhances glucose disposal and sharply reduces gluconeogenesis, indicating a potent role for this repressor pathway in whole-body metabolism. At the molecular level, genomic analysis in adipocytes revealed that BCL6 directly downregulates kinase signaling and fatty acid biosynthetic genes, similar to its actions as a transcriptional repressor in immune cells. Moreover, derepression of BCL6 in adipocytes mimics the adipose tissue transcriptomic profile of humans with ''metabolically normal obesity.'' The impact of adipocyte BCL6 ablation shown here is markedly distinguished from prior characterization of whole-body *Bcl6* knockout mice, which demonstrate variable degrees of growth retardation and ill health beginning at a few days to 3 weeks of life, with half dying before 5 weeks of age ([@R11]). Over 80% of Bcl6^−/−^ mice exhibit myocarditis and over 70% have pulmonary vasculitis with elevated levels of IL-4, −5, and −13, cytokines known to directly impact metabolism ([@R45]; [@R56]). Accordingly, prior metabolic analysis in total knockouts concluding that loss of BCL6 causes lipoatrophy was uninterpretable ([@R32]), and our work unambiguously identifies BCL6 as a direct regulator of adipocyte metabolism and insulin sensitivity.

Fat expansion occurs selectively in the ScAT of Bcl6^AKO^ mice, yet the transcriptomic changes incurred with *Bcl6* ablation and BCL6 genome-wide DNA binding are similar in the inguinal and perigonadal fat pads. Remarkably, we find that inducible deletion of adipocyte *Bcl6* in adult mice causes adipose tissue hypertrophy in all white adipose tissue depots, more consistent with our genomic data. Hence, the selective subcutaneous adipocyte hypertrophy in Bcl6^AKO^ mice reflects a distinction in depot development. The means by which in utero deletion of *Bcl6* becomes ''compensated'' in visceral depots to prevent adipocyte hypertrophy is unknown, but other studies have documented cellular differences between depots that may influence developmental phenotypes in adipose tissue and favor subcutaneous over visceral growth ([@R2]; [@R35]). Adi-poq-Cre targets a developmental population of proliferative and highly adipogenic progenitors present in inguinal subcutaneous, but not perigonadal, adipose tissue ([@R23]), which has been linked to depot-specific adiposity in knockouts of *Zfp423* ([@R50]; [@R59]). Accordingly, the timing of Adipoq-Cre expression in utero could play a role in the depot-specific phenotype of Bcl6^AKO^ mice. Finally, distinct transcriptional requirements have been documented in adipogenic development during embryogenesis versus adulthood even within the same depot ([@R68]), which could also contribute to the depot-selective versus global expansion of adipose tissue in Bcl6^AKO^ and i-Bcl6^AKO^ mice, respectively. Studies to further define the cell and molecular requirements for *Bcl6* ablation to expand adipocytes may provide insight into the differences between these models and the developmental basis for body fat distribution.

Our identification of BCL6 as a repressor of adipose tissue expansion shares features with other mouse models of healthful obesity, including transgenic adipocyte overexpression of *Glut4* ([@R51]; [@R73]), mitoNEET ([@R31]), adiponectin ([@R30]), and *Cidea* ([@R1]), or genetic deletion models targeting collagen VI ([@R29]) or *Pten* ([@R39]). Although these molecules are quite varied in their cellular roles, they commonly impact growth pathway signaling, *de novo* adipocyte lipogenesis, and insulin-sensitizing adipokines or lipokines. Of note, however, in most of these other models, healthy adipose tissue expansion is only observed in states of overnutrition. In contrast, Bcl6^AKO^ mice exhibit spontaneously increased adipose tissue mass and enhanced insulin sensitivity even in the absence of a HFD.

The basis by which *Bcl6* deletion in adipocytes confers insulin sensitivity to the liver and other tissues merits further inquiry, but changes in circulating adipokine and lipokines may play important roles. Indeed, increased circulating adiponectin has powerful stimulatory effects to activate ceramidase and mitigate lipotoxic mediators ([@R22]; [@R72]), consistent with the reduced levels of serum ceramides found in Bcl6^AKO^ mice. Moreover, we observed elevated levels of FAHFAs, including PAHSA, which has been inversely associated with human insulin resistance and may contribute to the improved metabolism via activation of GPR120 and GPR40 ([@R58]; [@R73]). However, the beneficial effects of exogenous FAHFAs have recently been challenged ([@R44]), raising the possibility that elevated FAHFAs in Bcl6^AKO^ mice could instead be a marker rather than a mediator of systemic insulin sensitivity in Bcl6^AKO^ animals.

Despite their metabolic health, Bcl6^AKO^ mice exhibit exacerbated adipose tissue inflammation and impaired brown fat activity, features that distinguish it from many other models with heightened insulin sensitivity. Although immune cell activation has generally been linked to insulin resistance ([@R16]), other studies conclude that inflammation is required for proper adipose tissue remodeling and insulin sensitivity ([@R59]; [@R71]). Notably, circulating levels of pro-inflammatory cytokines and chemokines were unchanged in Bcl6^AKO^ mice, indicating that inflammation within the adipose tissue did not ramify to other tissues in this model. Our findings suggest that either the benefits of *Bcl6* ablation, including reduced hepatic lipid accumulation and inflammation, outweigh the negative consequences of local adipose tissue inflammation or pro-inflammatory effects in adipose tissue could even contribute to the improved metabolic state of Bcl6^AKO^ animals. Although impaired brown fat function has generally been linked to adverse metabolic health ([@R3]), Bcl6^AKO^ mice manifest reduced BAT glucose uptake. These findings suggest that BAT activity and whole-body insulin sensitivity can be dissociated.

Deletion of *Bcl6* in adipocytes increases *de novo* lipogenesis, yet BCL6 does not repress the expression of ''classical'' lipo-genic enzymes and transporters such as *Scd1*, *Fasn*, *Dgat1*, and *Glut4*. Thus, our findings indicate that the lipogenic impact of BCL6 ablation is likely to derive from post-transcriptional changes in enzyme activities or pro-anabolic changes in substrates and cofactors. Notably, previous work has demonstrated that lipogenic gene expression and lipogenesis can be uncoupled. For example, in *ob*/*ob* mice, the expression of lipogenic genes is reduced, yet *de novo* lipogenesis is sharply increased in their adipose tissues ([@R40]; [@R55]; [@R63]). BCL6-repressed growth factors and signaling components, including IGF, AKT, and PTEN, are known to enhance the activities of anabolic enzymes and the synthesis of metabolites, which can be limiting in lipogenic reactions ([@R54]; [@R70]). Future studies are warranted to determine the impact of adipocyte BCL6 ablation on intermediary metabolism and flux, which may provide further insight into its anabolic impact on adipocytes and whole-body insulin sensitivity.

Aside from PPARg ([@R53]), BCL6 represents one of the only examples of a transcriptional regulator of healthful adiposity. BCL6 has been previously proposed to antagonize STAT5, yet growth hormone-STAT5 signaling has lipolytic effects to potently suppress adipose tissue mass ([@R28]). The unexpected lipogenic expansion of adipose tissue in Bcl6^AKO^ mice suggests a more complex, non-binary interrelationship between these transcription factors. Given that pharmacologic inhibitors of BCL6 have been developed to target selective interactions between BCL6 and its co-repressors ([@R9]), these findings raise the possibility that BCL6 de-repression could represent an insulin-sensitizing strategy to be tested in future work.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  REAGENT or RESOURCE                                                        SOURCE                                                                                                IDENTIFIER
  -------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- --------------------------------------
                                                                                                                                                                                   

  Antibodies                                                                                                                                                                       

                                                                                                                                                                                   

  BCL6                                                                       Santa Cruz Biotechnology                                                                              Cat\# sc-7388; RRID: AB_2063455

  BCL6                                                                       Custom polyclonal antibody                                                                            N/A

  Guinea pig IgG                                                             Rockland antibodies & assays                                                                          Cat\# 006--0102; RRID: AB_840780

  Phospho-Akt (Ser473)                                                       Cell Signaling Technology                                                                             Cat\# 5012; RRID: AB_2224726

  Akt (Pan)                                                                  Cell Signaling Technology                                                                             Cat\# 4691; RRID: AB_915783

  Phospho-IR                                                                 Cell Signaling Technology                                                                             Cat\# 2969; RRID: AB_11178660

  IR                                                                         Cell Signaling Technology                                                                             Cat\# 3020; RRID: AB_2249166

  Beta actin                                                                 Sigma-Aldrich                                                                                         Cat\# A1978; RRID: AB_476692

  Beta tubulin                                                               Sigma-Aldrich                                                                                         Cat\# T4026; RRID: AB_477577

  Horseradish peroxidase mouse secondary                                     Jackson ImmunoResearch Labs                                                                           Cat\# 115--035-174; RRID: AB_2338512

  Horseradish peroxidase rabbit secondary                                    Jackson ImmunoResearch Labs                                                                           Cat\# 211--032-171; RRID: AB_2339149

                                                                                                                                                                                   

  Chemicals, Peptides, and Recombinant Proteins                                                                                                                                    

                                                                                                                                                                                   

  Collagenase D                                                              Roche diagnostics                                                                                     CAS\#11088882001

  Dispase II                                                                 Sigma-Aldrich                                                                                         D4693

  IBMX                                                                       Sigma-Aldrich                                                                                         I5879

  Dexamethasone                                                              Sigma-Aldrich                                                                                         D4902

  Rosiglitazone                                                              Sigma-Aldrich                                                                                         R2408

  Tamoxifen                                                                  Sigma-Aldrich                                                                                         T5648

  Oil red O                                                                  Sigma-Aldrich                                                                                         O0625

  Humulin-100                                                                Eli Lilly                                                                                             N/A

  CL-316,246                                                                 Cayman Chemicals                                                                                      17499

  Isoproterenol                                                              Sigma-Aldrich                                                                                         I6379

  Disuccinimidyl glutarate                                                   Proteochem                                                                                            C1104

  Formaldehyde                                                               Polysciences, Inc.                                                                                    Cat\#18814

  Doxycycline hyclate                                                        Sigma-Aldrich                                                                                         D9891

  Deuterium oxide                                                            Sigma-Aldrich                                                                                         151882

  Fmoc chloride                                                              Sigma-Aldrich                                                                                         23186

  *N*- \[4-(Amino methyl)phenyl\] pyridinium                                 [@R65]                                                                                                N/A

  14-Fludeoxyglucose                                                         Sofie Biosciences                                                                                     N/A

  14C-Palmitic acid                                                          MP Biomedicals                                                                                        011219583

                                                                                                                                                                                   

  Critical Commercial Assays                                                                                                                                                       

                                                                                                                                                                                   

  NEFA assay kit                                                             Wako diagnostics                                                                                      99934691

  Glycerol assay kit                                                         Sigma-Aldrich                                                                                         MAK117

  Triglyceride assay kit                                                     Thermo Fisher Scientific                                                                              TR22421

  Mouse insulin ELISA kit                                                    Crystal Chem                                                                                          Cat\#90080

  Mouse Adiponectin ELISA kit                                                EMD Millipore                                                                                         EZMADP-60K

  Mouse adipokine MILLIPLEX-TNFa, IL-6, MCP-1, Leptin, Resistin, and PAI-1   EMD Millipore                                                                                         MADKMAG-71K

  KAPA hyper prep kit                                                        KAPA biosystems                                                                                       KK8504

  TruSeq Stranded mRNA kit                                                   Illumina                                                                                              20020595

                                                                                                                                                                                   

  Deposited Data                                                                                                                                                                   

                                                                                                                                                                                   

  Raw and analyzed RNA-seq data                                              This paper                                                                                            GEO: GSE113408

  Raw and analyzed ChIP-seq data                                             This paper                                                                                            GEO: GSE113408

                                                                                                                                                                                   

  Experimental Models: Cell Lines                                                                                                                                                  

                                                                                                                                                                                   

  3T3L-1                                                                     ATCC                                                                                                  CL-173

                                                                                                                                                                                   

  Experimental Models: Organisms/Strains                                                                                                                                           

                                                                                                                                                                                   

  B6.FVB-Tg(Adipoq-cre)1Evdr/J                                               The Jackson Laboratory                                                                                028020

  Bcl6^fl/fl^                                                                This paper                                                                                            N/A

  AdipoChaser (*adnP-rtTA*,*TRE-cre*, *Rosa26-loxP- stop-loxP-lacZ*)         [@R66]                                                                                                N/A

  B6.Cg-Tg(CAG-cre/Esr1\*)5Amc/J                                             The Jackson Laboratory                                                                                004682

  B6;129-Gt(ROSA)26Sortm5(CAG-Sun1/sfGFP)\                                   The Jackson Laboratory                                                                                021039
  Nat/J                                                                                                                                                                            

  C57BL/6J mouse                                                             The Jackson Laboratory                                                                                N/A

                                                                                                                                                                                   

  Oligonucleotides                                                                                                                                                                 

                                                                                                                                                                                   

  Primers for qRT-PCR                                                        [Table S2](#SD1){ref-type="supplementary-material"}                                                   N/A

  Primers for ChIP-PCR                                                       [Table S3](#SD1){ref-type="supplementary-material"}                                                   N/A

                                                                                                                                                                                   

  Software and Algorithms                                                                                                                                                          

                                                                                                                                                                                   

  Graph Pad Prism 7.0                                                        GraphPad Software                                                                                     

  Image Pro                                                                  Media Cybernetics                                                                                     N/A

  RNA Express                                                                <https://support.illumina.com/sequencing/sequencing_software/basespace.html>                          N/A

  HOMER                                                                      <http://homer.ucsd.edu/homer/>                                                                        N/A

  Morpheus                                                                   <https://software.broadinstitute.org/morpheus/>                                                       N/A

  Metascape                                                                  [http://metascape.org/gp/index.html\#/main/step1](http://metascape.org/gp/index.html%23/main/step1)   N/A

  BETA                                                                       <http://cistrome.org/BETA/>                                                                           N/A

  ImageJ                                                                     <https://imagej.nih.gov/ij/>                                                                          N/A

  Cellometer K2                                                              Nexcelom Bioscience                                                                                   N/A

  Biorad CFX manager                                                         Biorad                                                                                                \#184500

                                                                                                                                                                                   

  Other                                                                                                                                                                            

                                                                                                                                                                                   

  High fat diet                                                              Research Diets                                                                                        D12451

  Tissue Homogenizer                                                         MoBio PowerLyzer 24 Homogenizer                                                                       N/A

  Mouse MRI machine                                                          EchoMRI                                                                                               N/A

  qPCR machine                                                               Biorad CFX384 Touch                                                                                   N/A

  NextSeq 500 Sequencer                                                      Illumina                                                                                              N/A

  Metabolic Chambers                                                         TSE systems                                                                                           N/A

  Nanoscan                                                                   Mediso medical imaging systems                                                                        N/A

  Altis triple-quadrupole and Q-Exactive mass spectrometer                   Thermo Fisher Scientific                                                                              N/A
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CONTACT FOR REAGENT AND RESOURCE SHARING {#S18}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Grant Barish (<grant.barish@northwestern.edu>).
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### Animals {#S20}

Bcl6^fl/fl^ mice were generated through the UC Davis Mouse Biology Program by engineering loxP sites between exons 5 and 6 of the mouse Bcl6 locus. Cre-mediated deletion creates a frameshift mutation, resulting in a protein of 138 amino acids (compared to 708 amino acids in wild-type Bcl6) lacking exons 5 -- 10 and the zinc finger DNA binding domain. Bcl6^fl/fl^ mice were crossed with Adipoq-Cre mice (Jackson Laboratories, Stock \#028020) to generate Bcl6^fl/fl^; Adipoq-Cre mice (herein referred to as Bcl6^AKO^ mice). Bcl6^fl/fl^mice were also crossed with transgenic mice encoding tetracycline transactivator (rtTA) under the control of *adiponectin* promoter and cre recombinase expressed from a promoter containing Tet response element (TRE-cre) ([@R66]), which were kindly provided by Dr. Philipp Scherer (UTSW), to generate animals for doxycycline-inducible *Bcl6* deletion in adipocytes (i-Bcl6^AKO^ mice). During Dox treatment, 9-week old male mice were limited to drinking water containing 2 mg/ml doxycycline for 7 days to induce *Bcl6* deletion. Additionally, Bcl6^fl/fl^ mice were crossed to animals expressing tamoxifen-inducible Cre from the chicken beta actin promoter, CAG-Cre-ER™ mice (Jackson Laboratories, Stock \#004682) for primary preadipocyte differentiation studies. Sun1-sfGFP-myc (Jackson Laboratories, Stock \#021039) were further backcrossed to C57BL/6J mice for seven generations and crossed with Adipoq-Cre mice to generate Adipoq-Cre; Sun1-sfGFP-myc mice (Adipo-Sun1-sfGFP-myc mice) for ChIP-seq. Unless otherwise stated, mice were maintained on a 14:10 light: dark (LD) cycle with free access to standard chow and water. We provided either a standard chow or high fat diet (HFD; 45% of kcal from fat, 35% of kcal from carbohydrate and 20% of kcal from protein, Research Diets) *ad libitum*. 9--12 week old male and female littermates were used for studies conducted on standard chow, or HFD was given to mice beginning at these ages and continued for 8 -- 12 weeks as indicated. All animal care and use procedures were conducted in accordance with regulations of the Institutional Animal Care and Use Committee at Northwestern University.

### In vitro models {#S21}

Primary adipocytes: Fat depots were dissected from mice (6--8 weeks of age), washed in PBS, minced and incubated in digestion buffer (PBS, 1.5U/ml Collagenase D, 2.4U/ml Dispase II, 10mM CaCl~2~) for 30--45 minutes at 37^°^C with shaking to isolate SVF fractions. Digested tissues were centrifuged to pellet the stromal vascular cells, which were re-suspended in growth media (DMEM/F12 containing 10% fetal bovine serum (FBS), antibiotic and antimycotic (anti-anti, ThermoFisher), added to collagen coated plates, and incubated at 5% CO~2~. Medium was refreshed to remove floating cells 2 hours after plating.

METHOD DETAILS {#S22}
--------------

### *In vitro* differentiation of preadipocytes into adipocytes {#S23}

Once stromal vascular cells or 3T3L-1 cells reached confluency, they were differentiated by changing the medium to DMEM containing 10% fetal bovine serum 1% anti-anti, 0.5 mM IBMX, 0.25 mM dexamethasone, 2 mM rosiglitazone and 1g/ml insulin. After 2 days, the medium was changed to DMEM containing 10% fetal bovine serum 1% anti-anti 1 g/ml insulin for 48 hours. On day 5, the medium was changed to basal medium (DMEM containing 10% fetal bovine serum 1% anti-anti). Cells were harvested for assays at specified time points. For *in vitro* deletion studies in Bcl6^fl/fl^;CAG-Cre-ER™ SVF-derived preadipocytes, confluent cells were treated with 1mM tamoxifen or ethanol for 24 hours prior to induction of differentiation.

### Oil Red O staining {#S24}

Differentiated adipocytes were fixed in 10% formalin for 10 minutes at room temperature. Following fixation, the cells were washed twice with deionized water and incubated in 60% isopropanol for 10 minutes. Next, isopropanol was removed, Oil Red O solution (2g Oil Red O in 1L of 60% isopropanol) was added, and cells were incubated for 10 minutes. After incubation, the Oil Red O solution was removed, and cells were washed four times with deionized water and imaged.

### Adipocyte size and number determination {#S25}

Adipocyte size was calculated using microscopic images (Zeiss Axio) of hematoxylin and eosin (H&E) stained adipocytes in both chow-fed and HFD-fed mice using Image Pro software (Media Cybernetics). Diameters were determined for at least 300 adipo-cytes/mouse using the count/size function. Adipocyte numbers were determined using a Cellometer K2 (Nexcelom Biosciences). After whole fat pads from one side of the body were collagenase digested as described above, the top adipocyte-containing layer was re-suspended in PBS with 2% FBS cells and labeled with dual fluorescence of Acridine Orange (AO) and Propidium iodide (PI) prior to determining adipocyte number/fat pad.

### Histological analysis {#S26}

Tissues were dissected and fixed in 10% formaldehyde overnight and transferred to 70% ethanol. Paraffin processing, embedding, sectioning and hematoxylin and eosin (H&E) staining were performed at Northwestern University's Mouse Histology & Phenotyping Laboratory (MHPL).

### Immunoblotting {#S27}

Cells or tissues were homogenized in RIPA buffer (1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) containing protease and phosphatase inhibitors (Roche). Total lysates were subjected to 10% SDS-PAGE and transferred to PVDF membranes. Membranes were probed with antibodies to BCL6 (Santa Cruz, sc-7388), p-AKT (Cell Signaling, D9E), total AKT (Cell Signaling, C67E7), p-IR (Cell Signaling, 19H7), b-IR (Cell Signaling, L55B10), b-ACTIN (Sigma, A1978), b-TUBULIN (Sigma, T4026). Primary antibody incubations were followed by incubations with horseradish peroxidase conjugated secondary antibodies (Jackson ImmunoResearch). Blots were visualized using enhanced chemiluminescent (ECL) horseradish peroxidase (HRP) substrate (Thermo Scientific SuperSignal West Pico or West Femto).

### Blood glucose measurements {#S28}

After a 5 hour fast, blood glucose levels were measured using an AlphaTRAK® Glucose Meter (Abbott Animal Health) from tail vein bleeds.

### Insulin signaling assays {#S29}

Insulin signaling tests were performed following a 5 hour fast. Tissues were quickly obtained and flash frozen 15 minutes after intraperitoneal injection of insulin (0.5U/kg lean mass; Humulin R U-100). Lysates were prepared for immunoblotting as described above.

### Hyperinsulinemic--euglycemic clamps {#S30}

Hyperinsulinemic--euglycemic clamps were performed on 8 week HFD-fed conscious, unrestrained male mice at the Mouse Metabolic Phenotyping Center (MMPC) of Vanderbilt University, <https://vmmpc.org/methods-standards/>.

### *In vivo* lipolysis assay {#S31}

Following a 5 hour fast, mice were given an IP injection of CL 316, 246 (1mg/kg, Cayman Chemical) and blood was collected for serum NEFA and glycerol analysis at 0, 15 and 60 min after injection.

### Ex vivo lipolysis assay {#S32}

Assays of inguinal subcutaneous fat explants were performed using 20 mg tissue pieces incubated in 200ml DMEM containing 2% FA-free BSA, with or without 1mM isoproterenol in 96 well plates at 37^°^C 5% CO~2~, and 95% humidified incubator for one hour. Medium was taken out after one hour and glycerol and NEFA release was quantified. DNA was extracted from the tissues as described above for data normalization.

### Fatty acid oxidation {#S33}

Fatty acid (FA) oxidation assay was performed as described elsewhere ([@R25]). Briefly, tissue was dounce homogenized in sucrose/Tris/EDTA buffer. FA oxidation in isolated adipose tissue mitochondria was determined by measuring ^14^CO~2~ production and incompletely oxidized ^14^C-labeled fatty acids derived from^14^C-palmitic acid (0.4 mCi/ml) after 1 hour incubation at 37^°^C. The buffer was acidified with 1M perchloric acid and maintained sealed for an additional 1 hour at room temperature. Acid soluble and filter-trapped radioactivity was quantified by scintillation counting. ^14^CO~2~ and acid production rates were normalized to mg protein content.

### Serum measurements {#S34}

Blood samples were collected after a 5 hour fast and serum was collected using clotting activator tubes (Sarstedt). Serum insulin (Crystal Chem) and adiponectin (EMD Millipore) were measured by ELISA according to manufacturer's instructions. TNFa, IL-6, MCP-1, Leptin, Resistin, and PAI-1 serum levels were measured using a Luminex multiplex kit (EMD Millipore) according to manufacturer's instructions. Serum NEFA (Wako diagnostics) and glycerol (Sigma) levels were measured using colorimetric assays.

### Triglyceride quantification in liver {#S35}

Lipid was extracted using the Folch method. Briefly, liver tissue samples were homogenized in chloroform: methanol (2:1 by volume). After an overnight extraction, 0.7% sodium chloride was added. The aqueous layer was aspirated and triplicate aliquots of the chloroform/lipid layer were dried under nitrogen gas. The lipid was reconstituted in isopropyl alcohol and assayed for triglyceride using colorimetric assays (Thermo Fisher).

### Indirect calorimetry {#S36}

Mice were individually housed in metabolic chambers (PhenoMaster, TSE Systems) to monitor food intake, locomotor activity and gas exchange. Chambers were maintained with 12-hr light/dark cycles. Following 48 hours of acclimatization, O~2~ consumption (VO~2~) and CO~2~ production (VCO~2~) were measured every 30 minutes for a total of 72 hours and used to determine the respiratory exchange ratio (RER = VCO2/VO2) and energy expenditure (EE = 3.185+1.232 x RER) x VO2). VO~2~, VCO~2~, and energy expenditure values were normalized to total body weight. Total locomotor activity was simultaneously measured on the X and Y axes using an infrared photocell beam interruption technique.

### DNA isolation and quantification {#S37}

Tissues were flash frozen upon necropsy and stored at ---80^°^C. DNA from frozen adipose tissues was isolated per manufacturer's instructions using DNeasy Blood and Tissue Kits (QIAGEN). Concentrations were analyzed using a NanoDrop spectrophotometer.

### RNA isolation and qPCR mRNA quantification {#S38}

Tissues were flash frozen upon necropsy and stored at ---80^°^C. RNA was isolated from 100mg of tissue using TRIzol reagent (Thermo Fisher) according to the manufacturer's protocol and purified using RNeasy columns (QIAGEN). cDNAs were synthesized using iScript cDNA synthesis kits (Bio-Rad). Quantitative real-time PCR analysis was performed with SYBR Green Master Mix (Bio-Rad) and analyzed using a Bio-Rad CFX384 Touch Real-Time PCR System. Expression levels were determined using the relative standard curve method and normalized to the housekeeping gene *36b4.* Primer sequences for qRT-PCR are listed in [Table S2](#SD1){ref-type="supplementary-material"}.

### RNA-sequencing and analysis {#S39}

Following RNA isolation, RNA quality was confirmed using a Bioanalyzer (Agilent), and sequencing libraries were constructed using Illumina TruSeq Stranded mRNA sample prep kits according to the manufacturer's instructions. Libraries were quantified using Bio-analyzer (Agilent) and qPCR-based quantification (Kapa Biosystems) and sequenced on an Illumina NextSeq 500 instrument using 75 bp paired-end reads (adipose tissue samples) or 75 bp single-end reads (liver samples). Sequenced reads were aligned to the mm10 reference mouse genome using STAR and differentially expressed RNAs were identified using DESeq2 (FDR-adjusted p value \< 0.05). STAR alignment and DESeq2 analysis were executed through the RNA Express BaseSpace application (Illumina). Ontology analysis was done using Metascape (<http://metascape.org/>), performed in March 2018. Heatmaps were generated using rlog stabilized counts. Promoter Motif analysis was done using HOMER. For Human microarray data and RNA-seq data comparison: Metascape multiple gene list analysis was performed using combined gene lists of Bcl6^AKO^ males and females (AKO/WT) converted to human gene identifiers, MNO post/pre and MAO post/pre microarray gene lists ([@R14]). The raw and processed data are deposited in the GEO database (accession number GEO: GSE113408).

### Chromatin immunoprecipitation {#S40}

Adipo-Sun1-sfGFP-myc mice were used for the specific isolation of adipocyte chromatin. Finely minced adipose tissue was fixed for 30 minutes in 2mM disuccinimidyl glutarate and then for 10 minutes in 1% formaldehyde. Fixed tissue was then dounced in homogenization buffer (5mM NaCl, 0.05mM EDTA pH 7.5, 5mM, 0.005% NP40, 0.01% Triton X-100) and filtered through a 30-micron mesh. Filtrates were centrifuged to pellet nuclei, which were thoroughly resuspended in homogenization buffer and affinity purified using anti-c-*myc* magnetic beads (Pierce). Isolated adipocyte nuclei were sonicated using a Diagenode Bioruptor. Sheared chromatin was incubated with antibodies against BCL6 (affinity-purified guinea pig IgG) and precipitated with M280 paramagnetic beads (ThermoFisher) coated with anti-guinea pig IgG. DNA was isolated using MinElute PCR purification columns (QIAGEN). ChIP qPCR assays were performed using duplicates. Primer sequences for ChIP-qPCR are listed in [Table S3](#SD1){ref-type="supplementary-material"}.

### ChIP-sequencing and analysis {#S41}

ChIP DNA libraries were prepared using KAPA Hyper Prep kits (Kapa Biosystems) per manufacturer's instructions and size selected using a PippenHT (Sage Science). Libraries were assessed with a Bioanalyzer (Agilent) and qPCR-based quantification (Kapa Bio-systems), and sequenced using 75bp single-end reads on an Illumina Next-Seq 500. Raw sequence reads were aligned to the mm10 reference genome using bowtie 1.1.1 with parameters ''--best'' and ''--m'' to ensure selection of uniquely mapped reads. Aligned reads were visualized using UCSC genome browser. Analysis was performed using HOMER. Tag directories were generated using ''makeTagDirectory'' using the -tbp 1 option. ChIP-Seq peaks were designated as regions with 4-fold enrichment over both the input sample and the local background and were normalized to 10 million reads using default parameters (FDR = 0.001) for the ''findPeaks'' command and specifying ''-style factor.'' Peaks were annotated to nearest genes using ''annotatePeaks.pl.'' To identify motifs, we scanned 200 bp windows surrounding peaks using ''findMotifsGenome.pl'' with standard background. Binding site gene ontology analysis was performed using GREAT (<http://great.stanford.edu/public/html/>) and default parameters, and sites were integrated with RNA-seq data using BETA ([@R67]) and default parameters.

### De novo lipogenesis {#S42}

The rates of tissue lipogenesis were determined following the incorporation of ^2^H from ^2^H~2~O into newly made TG-bound fatty acids and glycerol. Briefly, mice were given 0.7 mL intraperitoneal injections of ^2^H-labeled saline (9g of NaCl in 1,000 mL of 99.9% ^2^H~2~O) at 3 pm, returned to their cages and maintained on 6% ^2^H-labeled drinking water. After 24 hours, mice were euthanized and serum, liver, and adipose tissues were collected, weighed, and snap frozen. Sample processing and GC/MS analysis was performed as described previously ([@R6], [@R5]). The rate of triglyceride formation or triglycerogenesis was based on ^2^H label incorporation into C-H bonds of TG-bound glycerol. Data was normalized to tissue mass or DNA content, as indicated.

### Lipid extraction and lipid derivatization for lipidomic analysis {#S43}

Mice were euthanized and adipose tissues were harvested, weighed, snap frozen in liquid N~2~, and stored at ---80^°^C. Tissues were homogenized in 0.5 mL of ice-cold diluted PBS (0.1x) with a Potter-Elvehjem tissue grinder, or serum samples were collected as described previously. A pre-mixture of internal standards for quantification of all reported lipid classes was added based on the tissue DNA content and the volume of serum samples, respectively. Lipid extraction was performed by a modified Bligh and Dyer method as previously described ([@R64], [@R18]). All the lipid extracts were flushed with N~2~, capped, and stored at ---20^°^C. A portion of individual lipid extract was derivatized with fluorenylmethoxylcarbonyl (Fmoc) chloride for analysis of PE ([@R19]), and another part was reacted with *N*-\[4-(Aminomethyl)phenyl\]pyridinium in order to measure the levels of FAHFAs ([@R65]).

### Mass spectrometric analysis of lipids {#S44}

Mass spectrometric analysis of lipids was performed with an Altis triple-quadrupole mass spectrometer (Thermo Fisher Scientific, San Jose, CA) or a Q-Exactive mass spectrometer (Thermo Fisher Scientific, San Jose, CA) equipped with an automated nanospray device (Triversa Nanomate, Advion Biosciences, Ithaca, NY) and operated with Xcalibur software as previously described ([@R20]). Identification and quantification of all reported lipid molecular species were performed using an in-house automated software program ([@R69]). All adipose tissue or serum lipid levels were normalized to sample DNA content or serum volume, respectively.

### PET and CT image acquisition and analysis {#S45}

PET and CT imaging studies were performed with nanoScan8 (Mediso, Budapest, Hungary). The mice were positioned head-first prone on a plastic bed, with a nose cone providing 1.5% isoflurane throughout the scan. Body-temperature was monitored and maintained stable. A tail vein catheter was placed in each mouse while anesthetized to deliver 18F labeled Fluorodeoxyglucose (18-FDG) within the scanner. Radioactive tracers were obtained through commercial sources (Sofie, Chicago) and each dose was calibrated using a Capintec dose calibrator. A whole-body CT sequence was initially used with the following parameters (energy = 35 kVp, exposure time = 300 msec, exposure = 240 µAs, slice thickness = 0.137 mm, voxel size = 0.137 mm^3^). The 3D whole body CT images were reconstructed from the data and a material map was also generated to be used for attenuation correction during PET reconstruction. For all subjects, a PET scanning sequence was initiated 5--10 minutes after bolus injection of an FDG dose of \~1MBq/gram (of body-weight). A total acquisition time of 75 minutes from moment of injection was used to acquire the data. A list-mode acquisition modality was used to enable dynamic reconstruction of the acquired data with different temporal resolution throughout the whole scan. PET images were generated using an OSEM reconstruction approach and corrected for attenuation using the CT material maps. The final images yielded whole body FDG uptake-maps in 3D at a resolution of 0.7 3 0.7 3 0.7 mm^3^

All image analysis (for both PET and CT) was performed using commercial software VivoQuant (inviCRO, Boston, MA, USA). The analysis of the images to generate quantitative results for whole-body fat-content characterization was conducted the following way: 1) abdominal subcutaneous tissue regions were detected and manually delineated with CT volumes windowed between ---1000 to 1000 \[HU\] for optimal visual contrast. 2) visceral tissue regions were semi-automatically delineated by manually selecting the peritoneum, and automatically thresholding all voxels between ---500 and ---50 \[HU\] as visceral adipose tissue.

Selection of these ranges was based on calibration data that we obtained from fresh *ex-vivo* samples of different types of fat harvested from several mice (data not shown). 3D-renderings were generated from the corresponding 3D CT images using the segmentation outlines obtained with these threshold settings for each mouse. The rendered surfaces corresponding to the fat-tissue types were superimposed on corresponding skeletal maximum intensity projection images (MPI). PET was standardized across subjects to quantify glucose uptake and metabolism using standardized uptake value (SUV) maps generated from raw data using the conventional formula. To obtain an accurate measure of the regional uptake values for BAT, we used a hybrid approach for segmentation which relied on both PET and CT data. In the interscapular region, all voxels with CT values between ---300 and 150 \[HU\] and PET-SUV values greater than 2 were classified as BAT. The resulting volume and activity was chosen to be the corresponding BAT value. This enabled us to detect BAT regions of higher activity by controlling for BAT volume.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S46}
---------------------------------------

All data were expressed as the mean ± SEM. We used Microsoft Excel and GraphPad Prism 7.0 (GraphPad Software, Inc.) to perform the statistical analyses. For comparisons between two independent groups, a Student's t test was used and p \< 0.05 was considered statistically significant. For comparisons between three or more groups, two-way ANOVA with Bonferroni multiple comparisons testing was performed. Correlation coefficients were calculated using Pearson correlation or nonparametric Spearman correlation. All sample sizes, statistical test methods, and p values are listed in the figure legends.
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![BCL6 Is Expressed in Mature Adipocytes and Limits Subcutaneous Adiposity\
(A) qRT-PCR expression of *Bcl6* over a 7-day time course of 3T3L1 pre-adipocyte differentiation.\
(B) BCL6 and tubulin protein in 3T3L1 pre-adipocytes and differentiated (day 7) adipocytes. Western blot (top) and protein densitometry (below) are shown.\
(C) qRT-PCR expression analysis of *Bcl6* and mature adipocyte markers in 3T3L1 pre-adipocytes and differentiated (day 7) adipocytes.\
(D) Fat, lean, and total body mass in chow-fed control and Bcl6^AKO^ male mice at 8 weeks of age (left) and percent body fat (right). n = 10--11 per group.\
(E) Inguinal subcutaneous, perigonadal, and interscapular brown adipose tissue masses in chow-fed male Bcl6^fl/fl^ and Bcl6^AKO^ mice at 9 weeks of age. n = 8--9 per group.\
(F) Representative inguinal subcutaneous fat pads from chow-fed Bcl6^fl/fl^ and Bcl6^AKO^ male mice.\
(G) Representative three-dimensional CT scan reconstructions comparing inguinal subcutaneous (ScAT, pseudo-colored red) and visceral (VAT, pseudo-colored green) adipose tissues in chow-fed Bcl6^fl/fl^ and Bcl6^AKO^ male mice. Volumes for each are shown (right).\
(H) H&E staining of ScAT from chow-fed control and Bcl6^AKO^ male mice. Scale bar, 150 µM.\
(I) Adipocyte diameters determined from H&E stained sections of ScAT from chow-fed Bcl6^fl/fl^ and Bcl6^AKO^ male mice. n = 4 per group.\
(J) Adipocyte numbers per inguinal ScAT fat pad. n = 5 per group.\
(K) H&E stained sections of representative PgAT from chow-fed Bcl6^fl/fl^ and Bcl6^AKO^ male mice. Scale bar, 150 µM.\
(L) Fat, lean, and total body mass in control and Bcl6^AKO^ male mice fed a high-fat diet for 12 weeks (left) and percent body fat (right) in chow-fed Bcl6^fl/fl^ and Bcl6^AKO^ male mice. n = 9--12 per group.\
Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, n.s., not significant. See also [Figures S1 and S2](#SD1){ref-type="supplementary-material"}.](nihms-1517607-f0002){#F1}

![Ablation of BCL6 in Adipocytes Promotes Insulin Sensitivity\
(A and B) Fasting serum insulin (A) and blood glucose levels (B) in chow-fed or high-fat diet (HFD)-fed Bcl6^fl/fl^ and Bcl6^AKO^ mice. n = 9--11 per group.\
(C) Calculated insulin resistance based on Homeostasis Model Assessment-2 for chow-fed and HFD-fed Bcl6^fl/fl^ and Bcl6^AKO^ mice. n = 9--11 per group.\
(D) Glucose infusion rates during hyperinsulinemic-euglycemic clamps in Bcl6^fl/fl^ and Bcl6^AKO^ mice performed after 8 weeks of HFD. n = 9 per group.\
(E) Total glucose flux (Rd) before and during insulin clamps. n = 9 per group.\
(F) Tissue-specific glucose uptake under clamp conditions. n = 9 per group.\
(G) Plasma free fatty acids under basal and insulin clamped conditions. n = 9 per group.\
(H) Endogenous glucose production plotted before and during clamping (left) or in relation to plasma insulin levels (right) in Bcl6^fl/fl^ and Bcl6^AKO^ mice. n = 9 per group.\
(I) Plasma insulin concentrations under basal and insulin clamped conditions. n = 9 per group.\
Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, n.s., not significant. See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1517607-f0003){#F2}

![BCL6 Governs Healthful Adipose Tissue Gene Expression\
(A and B) Rates of palmitate synthesis (A) and triglycerogenesis (B) in Bcl6^fl/fl^ and Bcl6^AKO^ mice in ScAT, and PgAT determined by ^2^H incorporation and normalized to DNA. n = 7 per group.\
(C) mRNA sequencing data from inguinal subcutaneous adipose tissue and perigonadal adipose tissue plotted as log~2~ fold change in expression in male Bcl6^AKO^ mice over WT (wild-type) controls (Bcl6^fl/fl^). Correlation coefficient (r) for all significantly regulated genes in either fat depot is listed. n = 4 per group.\
(D and E) Metascape gene list ontology analysis of genes upregulated (D) and downregulated (E) in ScAT and PgAT of Bcl6^AKO^ mice compared to controls.\
(F) qRT-PCR quantification of growth and lipid-regulatory genes in ScAT of Bcl6^AKO^ and control mice.\
(G) Metascape gene list ontology analysis comparing differentially upregulated genes in ScAT of Bcl6^AKO^ mice to gene expression changes in the subcutaneous adipose tissues of metabolically abnormal obese (MAO) and metabolically normal obese (MNO) human subjects following \~6% weight gain (p \< 0.1).\
Data are represented as mean ± SEM. n = 4 per group. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1517607-f0004){#F3}

![BCL6 Directly Represses Lipid Biosynthetic and Growth Genes\
(A) Scheme for adipocyte-specific ChIP-seq *in vivo* using Adipo-Sun1-sfGFP-myc mice. Fat pads were harvested, fixed, and homogenized. Adipocyte nuclei were precipitated using myc antibody-coated beads, lysed, and sonicated. Sheared chromatin was immunoprecipitated using BCL6-specific antibody, and the isolated DNA was sequenced.\
(B) Mouse phenotype gene ontologies for BCL6 binding sites in subcutaneous adipocytes.\
(C) Motif analysis in BCL6 ChIP-seq identified peaks from subcutaneous and perigonadal adipocytes.\
(D) Bar graph showing number of targets transcriptionally altered (up or down) and directly bound by BCL6 in ScAT and PgAT.\
(E) Representative genome browser tracks along the Fads1 (top) and Igf2 (bottom) genes for BCL6 ChIP-seq in subcutaneous adipocytes and RNA-seq in ScAT of Bcl6^fl/fl^ and Bcl6^AKO^ mice.\
(F and G) Directly upregulated (F) and downregulated (G) target gene ontology analysis of ChIP-seq binding sites associated with differentially expressed genes in Bcl6^AKO^ ScAT and PgAT.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1517607-f0005){#F4}

![Adipocyte *Bcl6* Ablation Produces an Insulin-Sensitizing Milieu of Lipokines and Adipokines\
(A) Fatty acid esters of hydroxy fatty acid (FAHFA) in ScAT (left, n = 3 per group) and serum (right, n = 6 per group) of Bcl6^fl/fl^ and Bcl6^AKO^ mice.\
(B) ScAT (left, n = 3 per group) and serum (right, n = 6 per group) FAHFAs in Bcl6^AKO^ and Bcl6^fl/fl^ mice.\
(C) Serum ceramide levels of chow-fed Bcl6^AKO^ and Bcl6^fl/fl^ mice. n = 6 per group.\
(D) Serum adiponectin in chow-fed (left) and HFD-fed (right) mice. n = 9--10 per group.\
Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. See also [Figures S5 and S6](#SD1){ref-type="supplementary-material"}.](nihms-1517607-f0006){#F5}

![Adipocyte *Bcl6* Deletion Protects against Hepatic Insulin Resistance and Steatosis\
(A) Insulin-stimulated insulin receptor (IR) and AKT phosphorylation in livers of Bcl6^fl/fl^ and Bcl6^AKO^ mice on chow diet (left). Densitometry analysis (right). n = 4--5 per group.\
(B) Rates of total liver palmitate synthesis in chow-fed Bcl6^fl/fl^ and Bcl6^AKO^ mice. n = 7 per group.\
(C) Heatmap of differentially regulated genes in livers of *ad lib* chow-fed Bcl6^fl/fl^ and Bcl6^AKO^ mice. n = 4 per group.\
(D) Gene ontology analysis of differentially expressed genes in livers of chow-fed Bcl6^fl/fl^ and Bcl6^AKO^ mice.\
(E) Top-scoring motifs in the promoters of differentially regulated genes in livers of chow-fed Bcl6^fl/fl^ and Bcl6^AKO^ mice.\
(F) Liver weights in chow-fed and HFD-fed Bcl6^fl/f^ and Bcl6^AKO^ mice. n = 7--9 per group.\
(G) Liver triglyceride content in chow-fed and HFD-fed Bcl6^fl/fl^ and Bcl6^AKO^ mice. n = 7--9 per group.\
(H) H&E staining of representative livers from Bcl6^fl/fl^ and Bcl6^AKO^ mice after 12 weeks of HFD. Scale bar, 150 mM.\
(I) qRT-PCR expression analysis of inflammatory genes in livers of Bcl6^fl/fl^ and Bcl6^AKO^ mice after 12 weeks of HFD. n = 6--7 per group.\
Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms-1517607-f0007){#F6}

###### Highlights

-   *Bcl6* deletion in adipocytes leads to subcutaneous adipose tissue expansion

-   Loss of *Bcl6* in adipocytes improves insulin sensitivity and protects from steatosis

-   BCL6 directly represses genes controlling fatty acid biosynthesis and cell growth

-   *Bcl6* ablation in adipocytes increases adiponectin and FAHFAs
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